Contract Research Organisation (CRO) Covance has appointed two experienced scientists to senior-level appointments.
The Oncology division will be led by Robert Wasserman, new VP and Global Therapeutic Area Head. Wasserman’s expertise lies in oncology translational medicine, including preclinical, clinical, biomarker and companion diagnostic drug development. He will be responsible in his new role for scientific strategy for the oncology and hematology therapeutic areas.
Before joining Covance, Wasserman worked for 15 years in the pharmaceutical industry, most recently at Hoffmann-La Roche as Site Head of Academic Alliances, Pharma Research and Early Development (pRED) for the Translational Clinical Research Center.
Rogelio Mosqueda-Garcia has been named Covance’s Global VP of Early Clinical Services within Medical and Scientific Affairs.
He is a prominent clinical pharmacologist with experience in translational and experimental medicine. He will provide scientific direction for the company’s Clinical Pharmacology Services and Early Clinical Development groups.
Mosqueda-Garcia previously served as Executive Director in Clinical Pharmacology at AstraZeneca Pharmaceuticals and held senior roles at Bristol-Myers Squibb and DuPont Pharmaceuticals.
Covance recently announced the launch of MarketPlace, a tool to securely connect its emerging biotech clients with established pharmaceutical clients.
Copyright - Unless otherwise stated all contents of this web site are © 2014 - William Reed Business Media SAS - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions
Catering for low value, high volume customers as well as the growing number of firms developing complex...
Clinverse, Intertek and inVentiv are among the pharma services companies announcing new staff this week.
In an Outsourcing-Pharma sporting special, we reveal why GSK will not be at the Rio Olympics, why...
This week's round-up of who's going places in contract research, manufacturing and services.
The latest faces in drug discovery, CROs, and research charities.